MALT lymphoma and erosive and ulcerative lesions of the stomach: modern diagnostic approaches and own clinical observation

Due to the pronounced polymorphism of stomach MALT-lymphoma endoscopic manifestations, often mimicking inflammatory changes of various etiologies, difficulties arise in the timely diagnosis of this disease. The alertness of the endoscopist and the use of integrated approaches to endoscopic diagnosis, taking into account the existing criteria for differential diagnosis, will undoubtedly improve the results of treatment.

1. Davydov M.I., Aksel E.M. The incidence of malignant neoplasms of the population of Russia and the CIS countries in 2007. Vestnik RONTS im. N.N. Blokhina = Bulletin of the N.N. Blokhin Russian Cancer Research CenterRONC 2009;20(3):52–90. (In Russ.).

2. Gan J.L., Tang Z.J. Clinical, endoscopic and pathological features of primery colorectal non-Hodgkin lymphoma: 24 cases report. Zhonghua Wei Chang Wai Ke Za Zhi 2006;9(6):502–5.

3. Ferreri A.J., Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 2009;265(4):421–38. DOI: 10.1111/j.1365-2796.2009.02083.x.

4. Kriachok I.A., Ulyanchenko K.O., Kadnikova T.V. et al. MALT-lymphoma: etiology, pathogenesis, classification, clinical issues. Klinicheskaya onkologiya = Clinical Oncology 2017:1:33–6. (In Russ.).

5. Farinha P., Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23(26):6370–8. DOI: 10.1200/JCO.2005.05.011.

6. Ming-Quing Du. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol 2007;47(2):31–42. DOI: 10.3960/jslrt.47.31.

7. Morgner A., Schmelz R., Christian Thiede C. et al. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007;13(26):3554–66. DOI: 10.3748/wjg.v13.i26.3554.

8. Malikhova O.A. A modern strategy for comprehensive endoscopic diagnosis and monitoring of nonHodgkin lymphomas of the stomach. Thesis ... of doctor of medical sciences. Moscow, 2010. (In Russ.).

9. Ledin V., Seryakov A.P., Astashov B.L. MALT-lymphoma of the stomach: clinical features, diagnosis and treatment. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology 2011;21(1):69–78. (In Russ.).

10. Zucca E., Dreyling M. MALT lymphoma. ESMO clinical recommendations for diagnosis, treatment and follow-up. Minimum clinical guidelines from the European Society of Medical Oncology (ESMO). Eds.: S.A. Tyulyandin, D.A. Nosov, N.I. Perevodchikova. Moscow: Publishing Group of N.N. Blokhin Russian Cancer Research Center, 2010. Pp. 276–278. (In Russ.).

11. Orlov E.Yu., Fedorov E.D., Dushkina V.F. Diagnostic potential of endoscopic ultrasonography for diseases of the upper digestive tract and pancreatobiliary area. Novye meditsinskiye tekhnologii. Novoe meditsinskoe oborudovanie = New medical technology. New Medical Equipment 2004;5:64–6. (In Russ.).

12. Cheung D.Y., Jung H.Y., Song H.J. et al. Guidelines of treatment for non-bleeding peptic ulcer disease. Korean J Gastroenterol 2009;54:285–97.

13. Kuipers E.J., Thijs J.C., Festen H.P. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl 2):59–69.

14. Carli D.M., Pires R.C., Rohde S.L. et al. Peptic ulcer frequency differences related to H. pylori or aines. Arq Gastroenterol 2015;52(1):46–9. DOI: 10.1590/S000428032015000100010.

15. Bordin D.S., Embutnieks Yu.V., Vologzhanina L.G. et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Terapevticheskiy arkhiv = Therapeutic Archive 2019;91(2):16–24. (In Russ.). DOI: 10.26442/00403660.2019.02.000156.

16. Bento-Miranda M., Figueiredo C., Shiratori S. et al. Helicobacter heilmannii sensu lato: an overview of the infection in humans. World J Gastroenterol 2014;20(47):17779–87. DOI: 10.3748/wjg.v20.i47.17779.

17. González-Pérez A., Sáez M.E., Johansson S. et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014;9(7):101768. DOI: 10.1371/journal.pone.0101768.

18. Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2019;18(1):5–66. (In Russ.). DOI: 10.15829/17288800-2019-1-5-66.

19. Masclee G.M., Valkhoff V.E., Coloma P.M. et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014;147(4):784–92. DOI: 10.1053/j.gastro.2014.06.007.

20. Wang P.Y., Chen H.P., Chen A. et al. Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. Biomed Res Int 2014;2014(3):616018. DOI: 10.1155/2014/616018.

21. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection – the Maastricht V/ Florence Consensus Report Gut 2012;61:646–64. DOI: 10.1136/gutjnl-2016-312288.

22. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002;359(9300):14–22. DOI: 10.1016/S0140-6736(02)07273-2.

23. Graham D.Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47:1665–78. DOI: 10.1023/a:1016495221567.

24. Sharma R., Organ C.H.Jr., Hirvela E.R. et al. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997;174(6):629–32. DOI: 10.1016/S0002-9610(97)00215-8.

25. Schuster K.M., Feuer W.J, Barquist E.S. Outcomes of cocaine-induced gastric perforations repaired with an omental patch. J Gastrointest Surg 2007;11(11):1560–3. DOI: 10.1007/s11605-007-0257-1.

26. Charpignon С., Lesgourgues B., Pariente A. et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/ NSAID intake. Aliment Pharmacol Ther 2013;38(8):946–54. DOI: 10.1111/apt.12465.

27. Wong G.L., Au K.W., Lo A.O. et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylorinegative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 2012;10:1124–9. DOI: 10.1016/j.cgh.2012.06.012.

28. Kanno T., Iijima K., Abe Y. et al. A multicenter prospective study on the prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drugsnegative idiopathic peptic ulcers in Japan. J Gastroenterol Hepatol 2015;30(5):842–8. DOI: 10.1111/jgh.12876.

29. Kanno T., Iijima K., Abe Y. et al. Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. J Gastroenterol 2013;48:483–90. DOI: 10.1007/s00535-012-0681-1.

30. Li L.F., Chan R.L., Lu L. et al. Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review) Int J Mol Med 2014;34(2):372–80. DOI: 10.3892/ijmm.2014.1786.

31. Garrow D., Delegge M.H. Risk factors for gastrointestinal ulcer disease in the us population. Dig Dis Sci 2010;55(1):66–72. DOI: 10.1007/s10620-008-0708-x.

32. Berkowitz L., Schultz B., Salazar G. et al. Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in crohn’s disease and ulcerative colitis. Front Immunol 2018;9:74. DOI: 10.3389/fimmu.2018.00074.

33. Parasher G., Eastwood G.L. Smoking and peptic ulcer in the Helicobacter pylori era. Eur J Gastroenterol Hepatol 2000;12(8):843–53. DOI: 10.1097/00042737-200012080-00003.

34. Ivashkin V.T., Sheptulin A.A., Mayev I.V. et al. Diagnostics and treatment of peptic ulcer: clinical guidelines of the Russian gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology 2016;26(6):40–54. (In Russ.). DOI: 10.22416/1382-4376-2016-26-6-4054

35. Kostyukevich O.I., Karnuta G.G. Symptomatic (secondary) gastroduodenal ulcers in clinical practice. RMJ = RMJ 2016;17:1153–7. (In Russ.).

36. Kastenbauer U., Ließ H., Kremer M. et al. CMV-associated gastric ulcer in an immunocompetent male patient. Internist (Berl) 2016;57(7):724–7. DOI: 10.1007/s00108016-0046-6.

37. Khan M.Q., Williams J. Anisakidosis: a fortuitous mimicker of gastrointestinal malignancy. BMJ Case Rep 2016. DOI: 10.1136/bcr-2016-216164.

38. Hamada K., Uedo N., Tomita Y. A bleeding gastric ulcer caused by anisakiasis. Ann Gastroenterol 2016;29(3):378. DOI: 10.20524/aog.2016.0039.

39. Hashimoto R., Chonan A. Gastric anisakiasis with a gastric ulcer. Intern Med 2016;55(24):3681. DOI: 10.2169/internalmedicine.55.7433.

40. Koçak E., Kılıç F., Akbal E. et al. The usefulness of ulcer size and location in the differential diagnosis of benign and malignant gastric ulcer. Wien Klin Wochenschr 2013;125(1–2):21–5. DOI: 10.1007/s00508-012-0309-8.

41. Koch P., Probst A., Berdel E. et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23:7050–9. DOI: 10.1200/JCO.2005.04.031.

42. Nakamura T., Seto M., Tajika M. et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol 2008;103(1):62–70. DOI: 10.1111/j.1572-0241.2007.01521.x.

43. Asano N., Iijima K., Koike T. et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review. World J Gastroenterol 2015;21(26):8014–20. DOI: 10.3748/wjg.v21.i26.8014.

44. Morgner A., Lehn N., Andersen L.P. et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000;118(5):821–8. DOI: 10.1016/s0016-5085(00)70167-3.

45. Govi S., Dognini G.P., Licata G. et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a singlecentre phase II trial. Br J Haematol 2010;150:226–9. DOI: 10.1111/j.1365-2141.2010.08179.x.

46. Kiesewetter B., Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 2013;122(8):1350–7. DOI: 10.1182/blood-2013-02-486522.

47. Tsang R.W., Gospodarowicz M.K., Pintilie M. et al. Localized mucosaa-ssociated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21(22):4157–64. DOI: 10.1200/JCO.2003.06.085.